Market Overview

MannKind Reports Positive Phase 3 Data from AFREZZA Study in Patients with Type 2 Diabetes

MannKind Corporation (NASDAQ: MNKD) today announced positive
preliminary results from Study 175, a Phase 3 clinical study of AFREZZA®
(insulin human [rDNA origin]) Inhalation Powder, an investigational,
ultra rapid-acting mealtime insulin therapy administered using
MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat™
inhaler), in patients with type 2 diabetes.

Highlights

AFREZZA combined with oral therapy, compared to oral therapy alone,
showed:

Superior reductions in A1c levels;

Significantly more patients reached A1c target levels;

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (MNKD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free